Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

BACKGROUND: With ocrelizumab another drug is available for the treatment of multiple sclerosis (MS). Little is known on the long-term use of ocrelizumab on immune cell subsets, and no surrogate markers are available. Rituximab (RTX) has been in off-label use for the treatment of MS, neuromyelitis op...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellrichmann, Gisa, Bolz, Jan, Peschke, Maren, Duscha, Alexander, Hellwig, Kerstin, Lee, De-Hyung, Linker, Ralf A., Gold, Ralf, Haghikia, Aiden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342886/
https://www.ncbi.nlm.nih.gov/pubmed/30377816
http://dx.doi.org/10.1007/s00415-018-9092-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342886/
https://www.ncbi.nlm.nih.gov/pubmed/30377816
http://dx.doi.org/10.1007/s00415-018-9092-4

Ejemplares similares